DRAM2 Knockout HGC-27 Polyclonal Cells

Product Type:
Polyclonal Cell Population
Species:
Homo sapiens (Human)
Tissue Source:
Stomach
Disease:
Carcinoma

Datasheet

A CRISPR/Cas9-edited polyclonal DRAM2 knockout cell population in HGC-27 human gastric carcinoma cells. DRAM2 is a lysosomal membrane protein that promotes autophagy and lysosomal acidification downstream of p53, interacting with BECN1 and UVRAG. Knockout of DRAM2 disrupts autophagic flux and lysosomal degradation, offering a model to investigate p53-dependent autophagy, gastric cancer cell homeostasis, and chemoresistance. Suitable for LC3-II/p62 Western blot, LysoTracker staining, and drug sensitivity assays.

Inquire Now

In stock

Ships next business day

Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice

Disclaimer:

For Research Use Only

Characteristics

Host Cell

HGC-27

Sex of Donor

Unknown

Age

Unknown

Derived From Site

Metastatic; Lymph node

Gene Name

DRAM2

Gene Identifier

NCBI Gene ID 128338

Morphology

Epithelial-like

Growth Mode

Adherent

Storage

Liquid nitrogen (LN2)
Culture Conditions

Growth medium

RPMI 1640

Supplement(s)

10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

Temperature

37°C

Atmosphere

5% CO₂
Quality Control

Sterility testing

The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Mycoplasma testing

Negative for mycoplasma through PCR analysis
Disclaimer

Intended Use

This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer

Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The DRAM2 Knockout HGC-27 Polyclonal Cells product provides a ready-to-use, CRISPR/Cas9-edited polyclonal knockout cell population targeting the DRAM2 gene in the HGC-27 human gastric carcinoma background.

This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, delivering a heterogeneous pool of cells with targeted DRAM2 inactivation.

The polyclonal format preserves population-level effects while enabling robust assessment of gene function in metastatic gastric cancer research.